Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment

Liu, Wanwan; Cheng, Ziting; Yao, Ke; Yang, Yu Min; Xu, Bohui; Su, Gaoxing

doi:10.3390/ijms18102029

Cited by 32 publications

(17 citation statements)

References 46 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gold nanoparticles (AuNPs) are used for biomedical applications in diagnostic, drug therapy, and imaging [1,2,3,4]. Gold nanostars, containing multiple sharp tips, are particularly attractive in imaging and diagnostic, as compared with their spherical counter parts [5,6].…”

Section: Introductionmentioning

confidence: 99%

A Metabolomic Approach for the In Vivo Study of Gold Nanospheres and Nanostars after a Single-Dose Intravenous Administration to Wistar Rats

et al. 2019

View full text Add to dashboard Cite

Gold nanoparticles (AuNPs) are promising nanoplatforms for drug therapy, diagnostic and imaging. However, biological comparison studies for different types of AuNPs fail in consistency due to the lack of sensitive methods to detect subtle differences in the expression of toxicity. Therefore, innovative and sensitive approaches such as metabolomics are much needed to discriminate toxicity, specially at low doses. The current work aims to compare the in vivo toxicological effects of gold nanospheres versus gold nanostars (of similar ~40 nm diameter and coated with 11-mercaptoundecanoic acid) 24 h after an intravenous administration of a single dose (1.33 × 1011 AuNPs/kg) to Wistar rats. The biodistribution of both types of AuNPs was determined by graphite furnace atomic absorption spectroscopy. The metabolic effects of the AuNPs on their main target organ, the liver, were analyzed using a GC-MS-based metabolomic approach. Conventional toxicological endpoints, including the levels of ATP and reduced and oxidized glutathione, were also investigated. The results show that AuNPs preferentially accumulate in the liver and, to a lesser extent, in the spleen and lungs. In other organs (kidney, heart, brain), Au content was below the limit of quantification. Reduced glutathione levels increased for both nanospheres and nanostars in the liver, but ATP levels were unaltered. Multivariate analysis showed a good discrimination between the two types of AuNPs (sphere- versus star-shaped nanoparticles) and compared to control group. The metabolic pathways involved in the discrimination were associated with the metabolism of fatty acids, pyrimidine and purine, arachidonic acid, biotin, glycine and synthesis of amino acids. In conclusion, the biodistribution, toxicological, and metabolic profiles of gold nanospheres and gold nanostars were described. Metabolomics proved to be a very useful tool for the comparative study of different types of AuNPs and raised awareness about the pathways associated to their distinct biological effects.

show abstract

Section: Introductionmentioning

confidence: 99%

A Metabolomic Approach for the In Vivo Study of Gold Nanospheres and Nanostars after a Single-Dose Intravenous Administration to Wistar Rats

et al. 2019

View full text Add to dashboard Cite

show abstract

“…2) In addition to superficial tumors, PTT combined with interventional technology has the potential to treat deep tumors ( Hu et al, 2017 ). 3) Targeted molecular modified nanoparticles are used to drug or nucleic acid delivery, and tumor-specific killing can be achieved after intravenous injection ( Zhu H. et al, 2017 ; Zhu X. et al, 2017 ). At present, PTT has attracted increasing attention as a non-invasive treatment.…”

Section: Np-based Photothermal and Photodynamic Immunotherapymentioning

confidence: 99%

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Liu

Huang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is a major cause of incidence rate and mortality worldwide. In recent years, cancer immunotherapy has made great progress in the preclinical and clinical treatment of advanced malignant tumors. However, cancer patients will have transient cancer suppression reaction and serious immune related adverse reactions when receiving immunotherapy. In recent years, nanoparticle-based immunotherapy, which can accurately deliver immunogens, activate antigen presenting cells (APCs) and effector cells, provides a new insight to solve the above problems. In this review, we discuss the research progress of nanomaterials in immunotherapy including nanoparticle-based delivery systems, nanoparticle-based photothermal and photodynamic immunotherapy, nanovaccines, nanoparticle-based T cell cancer immunotherapy and nanoparticle-based bacteria cancer immunotherapy. We also put forward the current challenges and prospects of immunomodulatory therapy.

show abstract

“…Similar to PDT, nanoparticle-based PTT for the treatment of cancer offers the following unique and advantageous features: (i) combination of a near-infrared (NIR) laser with nanoparticle-based photothermal agents allows target-focused and deeper penetration of the activating signal [119,120]; (ii) tumor-specific target molecules (peptides or nucleic acids) included in the nano-formulation can offer tumor-specific targeting and avoid offtarget systemic effects [118,121]; (iii) by combining PTT with interventional technologies for the delivery of light, PTT is not limited to superficial tumors, but can treat internal malignancies such as prostate and pancreatic cancer [13,[122][123][124]; (iv) PTT agents can be used for image-guided therapy using theranostic nanoparticles [13,[125][126][127]. In preclinical studies, PTT has been successful as a monotherapy or in combination with other therapies for the treatment of several malignancies including breast cancer, melanoma, and liver cancer in murine models [116,118,128].…”

Section: Photothermal Therapy (Ptt)mentioning

confidence: 99%

Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)

et al. 2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) causes selective damage to tumor cells and vasculature and also triggers an anti-tumor immune response. The latter fact has prompted the exploration of PDT as an immune-stimulatory adjuvant. PDT is not the only cancer treatment that relies on electromagnetic energy to destroy cancer tissue. Ionizing radiation therapy (RT) and photothermal therapy (PTT) are two other treatment modalities that employ photons (with wavelengths either shorter or longer than PDT, respectively) and also cause tissue damage and immunomodulation. Research on the three modalities has occurred in different “silos”, with minimal interaction between the three topics. This is happening at a time when immune checkpoint inhibition (ICI), another focus of intense research and clinical development, has opened exciting possibilities for combining PDT, PTT, or RT with ICI to achieve improved therapeutic benefits. In this review, we surveyed the literature for studies that describe changes in anti-tumor immunity following the administration of PDT, PTT, and RT, including efforts to combine each modality with ICI. This information, collected all in one place, may make it easier to recognize similarities and differences and help to identify new mechanistic hypotheses toward the goal of achieving optimized combinations and tumor cures.

show abstract

Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment

Cited by 32 publications

References 46 publications

A Metabolomic Approach for the In Vivo Study of Gold Nanospheres and Nanostars after a Single-Dose Intravenous Administration to Wistar Rats

A Metabolomic Approach for the In Vivo Study of Gold Nanospheres and Nanostars after a Single-Dose Intravenous Administration to Wistar Rats

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)

Contact Info

Product

Resources

About